Items tagged with Advocacy
Stop TB Partnership launches Challenge Facility for Civil Society Round 8 (post)
4 December 2017 – Geneva, Switzerland – Stop TB Partnership, with the support of USAID and the Global Fund to Fight AIDS, Tuberculosis and Malaria today launched the call for proposals for the eighth round of the Challenge Facility for Civil Society (CFCS).
GCTA newsletter: November 2017 issue (post)
The Global Coalition of TB Activists (GCTA) released the latest edition of its quarterly newsletter highlighting the GCTA's activities at the Global Ministerial Conference on TB held on 16-17 November 2017 in Moscow, Russia and the 48th Union World Conference on Lung Health held on 11-14 October 2017 in Guadalajara, Mexico.
Have your say: contribute to the UN’s work to end TB, HIV and viral hepatitis in the WHO European Region (post)
The WHO Regional Office for Europe is seeking input on a United Nations (UN) common position paper on ending tuberculosis (TB), HIV and viral hepatitis through intersectoral collaboration, drafted in collaboration with sister UN agencies. The consultation survey will remain available until 11 January 2018 and can be accessed here.
Tuberculosis: criteria for global leadership? (post)
Tereza Kasaeva is to be the new Director of WHO's Global Tuberculosis (TB) Programme. She joins WHO from Russia's Ministry of Health. But instead of a warm welcome, she will arrive in Geneva amid potentially disabling controversy.
WHO: New directors in leadership team selected on merit first (post)
The new World Health Organization director general last month announced a range of officials to serve as programme directors, touting the unusual achievement of naming almost all women to add to an overall women’s majority in the senior leadership of the organisation – a first for the UN. Now after some questions arose over the choice of a Russian official to head up efforts against tuberculosis, the WHO defended its choices as fully merit-based, including in an email to Intellectual Property Watch and its sister publication Global Health Policy News.
Securing a TB-free future through the visionary research of the CDC’s Tuberculosis Trials Consortium (post)
January 10, 2018 – The Tuberculosis Trials Consortium (TBTC) is a global leader in research and development for better tools to prevent, diagnose, and treat tuberculosis (TB). Housed within the U.S. Centers for Disease Control and Prevention (CDC), the TBTC conducts clinical research of high public health relevance and is key to strengthening domestic and global campaigns to eliminate TB. TBTC studies have produced several notable breakthroughs, including a shorter regimen for preventing TB (3HP) using isoniazid and rifapentine. The Community Research Advisors Group (CRAG) produced this briefing document to raise awareness of the TBTC’s legacy of accomplishments; highlight major advances in TB care resulting from TBTC studies; and make the case for increasing funding for TB research at CDC in line with the goals of the U.S. National Action Plan for Combatting Multidrug-Resistant Tuberculosis.
Public hearing in Azerbaijan Parliament: Global calls and commitments – TB fight in Azerbaijan Republic (post)
Public hearings were held on the 30th of January 2018 in Azerbaijan Parliament titled “Global calls and commitments – TB fight in Azerbaijan Republic”. The event was attended by Members of Parliament (MPs) governmental, national and international organizations, TB Azerbaijan Coalition members (TBAZC) and mass media. The following topics were covered: social support to TB patients, added values of CSOs in TB treatment and care, improving quality of TB treatment and care, need for government and civil society efforts in addressing the increasing level of drug resistant TB in the country, fight with TB stigma, ensuring sustainability of TB services after the Global Fund withdrawal, need for increasing TB awareness among general population and need for updating the “Azerbaijan TB Law”.
In the year of TB, advocates want more than a political commitment (post)
“We can’t continue to allow governments and … global health leaders to promise ending TB by 2030 … as long as they’re not even putting their best foot forward in the course of the next 12 months, or even 12 weeks.”
NIH experts call for transformative research approach to end TB (post)
A more intensive biomedical research approach is necessary to control and ultimately eliminate tuberculosis (TB), according to a perspective published in the March 2018 issue of The American Journal of Tropical Medicine and Hygiene. In the article, authors Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and Robert W. Eisinger, Ph.D., special assistant for scientific projects at NIAID, discuss the need to modernize TB research by applying new diagnostic, therapeutic, and vaccine approaches. The perspective is based on a lecture delivered by Dr. Fauci on Nov. 17, 2017 in Moscow at the first World Health Organization Global Ministerial Conference, “Ending TB in the Sustainable Development Era: A Multisectoral Response.”
MSF welcomes Members of the European Parliament response to the US pharmaceutical pressure to stop EU action on high drug prices (post)
6 March 2018 — The Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), two US pharmaceutical lobby groups, have requested the US Trade Representative (USTR) to place the European Union (EU) on its 2018 Special 301 Report. This highly controversial Report by the USTR is an annual unilateral review of the enforcement of intellectual property rights (IPR) in other countries, and used as means to pressure countries to comply with the US demands for tougher IP rules that would eventually benefit the US pharmaceutical industry.
Page 18 of 127 · Total posts: 0
←First 17 18 19 Last→